Live Breaking News & Updates on Analysts Expect For Zynerba|Page 1

The month of August has been hard one for cannabis drug stocks.
After Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported a pair of disappointing trial results in its Phase 2 STAR 1 and STOP trials, respectively, the company’s market cap went up in smoke to the tune of a more than 50 percent. Read More. ....

United States , United Kingdom , Buenos Aires , Distrito Federal , America Merrill Lynch , Cantor Fitzgerlad , Alejandra Villa , Gw Pharma Epidiolexthursday , Debra Borchardt , Elemer Piros , Michael Higgins , Jim Cramer , Alan Brochstein , Corey Davis , Carlos Kambourian , Marinus Pharmaceuticals Has , Zogenix Inc , Oppenheimer Downgrades Marinus Pharmaceuticals , Panel Vote , Gw Pharmaceuticals , Pfizer Inc , Cannabis Community , Competition And Markets Authority , Ovid Therapeutics Inc , Zynerba Pharmaceuticals Inc , Takeda Pharmaceutical Co Ltd ,